Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deborah Grady

Showing results (171-180 of 198) with videos related to

Pageof 20
Sort By:
Fertility and Sterility|December 15, 2015
PROMISe trial: a pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroidsVanessa L Jacoby, Maureen P Kohi, Liina Poder, et al.
Menopause (New York, N.Y.)|February 3, 2009
MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trialDeborah Grady, George F Sawaya, Karen C Johnson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 26, 2007
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart TrialKristine E Ensrud, John L Stock, Elizabeth Barrett-Connor, et al.
The American Journal of Cardiology|November 27, 2002
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trialNanette Kass Wenger, Elizabeth Barrett-Connor, Peter Collins, et al.
Journal of the National Cancer Institute|June 12, 2008
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary riskDeborah Grady, Jane A Cauley, Mary Jane Geiger, et al.
JAMA|July 2, 2002
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)Stephen Hulley, Curt Furberg, Elizabeth Barrett-Connor, et al.
Circulation|February 11, 2009
Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factorsPeter Collins, Lori Mosca, Mary Jane Geiger, et al.
Stroke|October 25, 2008
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart diseaseLori Mosca, Deborah Grady, Elizabeth Barrett-Connor, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 18, 2002
Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary diseaseDavid M Herrington, Eric Vittinghoff, Timothy D Howard, et al.
JAMA Internal Medicine|July 15, 2024
Randomized Clinical Trials That Advance Health and Health Equity: JAMA Internal Medicine Call for PapersTracy Y Wang, Giselle Corbie, Heather Gwynn Allore, et al.
Pageof 20

Showing results (171-180 of 198) with videos related to

Sort By:
Pageof 20
Fertility and Sterility|December 15, 2015
PROMISe trial: a pilot, randomized, placebo-controlled trial of magnetic resonance guided focused ultrasound for uterine fibroidsVanessa L Jacoby, Maureen P Kohi, Liina Poder, et al.
Menopause (New York, N.Y.)|February 3, 2009
MF101, a selective estrogen receptor beta modulator for the treatment of menopausal hot flushes: a phase II clinical trialDeborah Grady, George F Sawaya, Karen C Johnson, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 26, 2007
Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart TrialKristine E Ensrud, John L Stock, Elizabeth Barrett-Connor, et al.
The American Journal of Cardiology|November 27, 2002
Baseline characteristics of participants in the Raloxifene Use for The Heart (RUTH) trialNanette Kass Wenger, Elizabeth Barrett-Connor, Peter Collins, et al.
Journal of the National Cancer Institute|June 12, 2008
Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary riskDeborah Grady, Jane A Cauley, Mary Jane Geiger, et al.
JAMA|July 2, 2002
Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II)Stephen Hulley, Curt Furberg, Elizabeth Barrett-Connor, et al.
Circulation|February 11, 2009
Effects of the selective estrogen receptor modulator raloxifene on coronary outcomes in the Raloxifene Use for The Heart trial: results of subgroup analyses by age and other factorsPeter Collins, Lori Mosca, Mary Jane Geiger, et al.
Stroke|October 25, 2008
Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart diseaseLori Mosca, Deborah Grady, Elizabeth Barrett-Connor, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|June 18, 2002
Factor V Leiden, hormone replacement therapy, and risk of venous thromboembolic events in women with coronary diseaseDavid M Herrington, Eric Vittinghoff, Timothy D Howard, et al.
JAMA Internal Medicine|July 15, 2024
Randomized Clinical Trials That Advance Health and Health Equity: JAMA Internal Medicine Call for PapersTracy Y Wang, Giselle Corbie, Heather Gwynn Allore, et al.
Pageof 20